This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer
Journal of Translational Medicine Open Access 14 January 2024
-
Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer
Cell Death Discovery Open Access 06 March 2023
-
The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
Nature Communications Open Access 01 June 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Miyamoto H and Messing EM (2004) Early versus late hormonal therapy for prostate cancer. Curr Urol Rep 5: 188–196
Merrick GS et al. (2005) Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61: 32–43
Sandler HM (2004) Optimizing hormone therapy in localized prostate cancer: focus on external beam radiotherapy. J Urol 172 (Pt 2): S38–S41
D'Amico AV et al. (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292: 821–827
Messing EM et al. (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341: 1781–1788
Acknowledgements
The synopsis was written by Sandra Michelmore, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Glossary
- LOW RISK
-
Biochemical definition: PSA <10 ng/ml and Gleason score <7 (see GLEASON SCORE)
- INTERMEDIATE RISK
-
Biochemical definition: PSA <10 ng/ml and Gleason score >6, or PSA ≥10 ng/ml and Gleason score <7 (see GLEASON SCORE)
- BRACHYTHERAPY
-
Radiotherapy in which closed sources of radiation (e.g. seeds) are placed (e.g. by implantation) in or close to the area being treated
- BIOCHEMICAL RELAPSE
-
Defined according to the American Society for Therapeutic Radiology and Oncology consensus in patients who underwent brachytherapy or EBRT, and as PSA >0.5 ng/ml in those who underwent RRP
- GLEASON SCORE
-
Sum of grades assigned to the two largest cancerous areas of tissue samples; grades range from 1 (least aggressive) to 5 (most aggressive)
Rights and permissions
About this article
Cite this article
Miyamoto, H., Messing, E. & Chang, C. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?. Nat Rev Clin Oncol 2, 236–237 (2005). https://doi.org/10.1038/ncponc0168
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0168
This article is cited by
-
Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer
Journal of Translational Medicine (2024)
-
Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer
Cell Death Discovery (2023)
-
RETRACTED ARTICLE: Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer
Cancer Gene Therapy (2022)
-
The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
Nature Communications (2020)